Cumberland Pharmaceuticals Inc. (CPIX)
Largest Insider Buys in Sector
CPIX Stock Price History Chart
CPIX Stock Performance
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Insider Activity of Cumberland Pharmaceuticals Inc.
Over the last 12 months, insiders at Cumberland Pharmaceuticals Inc. have bought $0 and sold $0 worth of Cumberland Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Cumberland Pharmaceuticals Inc. have bought $117,041 and sold $839,622 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 360 shares for transaction amount of $799 was made by Krogulski Kenneth (director) on 2022‑12‑21.
List of Insider Buy and Sell Transactions, Cumberland Pharmaceuticals Inc.
| 2022-12-21 | Krogulski Kenneth | director | 360 0.0026% | $2.22 | $799 | -14.69% | ||
| 2022-12-21 | Galante Joseph C | director | 180 0.0013% | $2.22 | $400 | -14.69% | ||
| 2022-12-21 | Jones James | director | 88 0.0006% | $2.22 | $195 | -14.69% | ||
| 2022-12-20 | Krogulski Kenneth | director | 370 0.0027% | $2.31 | $855 | -16.44% | ||
| 2022-12-20 | Galante Joseph C | director | 200 0.0015% | $2.31 | $462 | -16.44% | ||
| 2022-12-20 | Jones James | director | 121 0.0009% | $2.31 | $280 | -16.44% | ||
| 2022-12-20 | Young Caroline | director | 109 0.0008% | $2.31 | $252 | -16.44% | ||
| 2022-12-19 | Krogulski Kenneth | director | 450 0.0032% | $2.21 | $995 | -16.20% | ||
| 2022-12-19 | Galante Joseph C | director | 250 0.0018% | $2.21 | $553 | -16.20% | ||
| 2022-12-19 | Jones James | director | 70 0.0005% | $2.21 | $155 | -16.20% | ||
| 2022-12-19 | Young Caroline | director | 30 0.0002% | $2.21 | $66 | -16.20% | ||
| 2022-12-16 | Krogulski Kenneth | director | 246 0.0017% | $2.22 | $546 | -18.94% | ||
| 2022-12-16 | Galante Joseph C | director | 100 0.0007% | $2.22 | $222 | -18.94% | ||
| 2022-12-16 | Jones James | director | 40 0.0003% | $2.22 | $89 | -18.94% | ||
| 2022-12-16 | Young Caroline | director | 20 0.0001% | $2.22 | $44 | -18.94% | ||
| 2022-12-15 | Krogulski Kenneth | director | 144 0.001% | $2.24 | $323 | -18.36% | ||
| 2022-12-15 | Galante Joseph C | director | 60 0.0004% | $2.24 | $134 | -18.36% | ||
| 2022-12-15 | Jones James | director | 20 0.0001% | $2.24 | $45 | -18.36% | ||
| 2022-12-15 | Young Caroline | director | 20 0.0001% | $2.24 | $45 | -18.36% | ||
| 2022-12-14 | Krogulski Kenneth | director | 320 0.0022% | $2.21 | $707 | -15.07% |
Insider Historical Profitability
| KAZIMI A J | Chairman and CEO | 5770563 38.7161% | $1.52 | 287 | 1 | <0.0001% |
| Greer Lawrence W | director | 496435 3.3307% | $1.52 | 0 | 2 | |
| Marstiller Jean W | Sr. VP & Corp. Secretary | 428198 2.8729% | $1.52 | 0 | 2 | |
| Edwards Robert | director | 400970 2.6902% | $1.52 | 1 | 1 | <0.0001% |
| Krogulski Kenneth | director | 204955 1.3751% | $1.52 | 303 | 0 | <0.0001% |
| Cearnal Martin E | Sr VP/Chief Commercial Officer | 178473 1.1974% | $1.52 | 172 | 0 | <0.0001% |
| JACOBS JOEY A | director | 88415 0.5932% | $1.52 | 38 | 0 | <0.0001% |
| Galante Joseph C | director | 57356 0.3848% | $1.52 | 304 | 0 | <0.0001% |
| Pavliv Leo | Sr. Vice President, Operations | 26445 0.1774% | $1.52 | 1 | 1 | <0.0001% |
| Jones James | director | 26293 0.1764% | $1.52 | 182 | 0 | <0.0001% |
| Young Caroline | director | 19587 0.1314% | $1.52 | 293 | 0 | <0.0001% |
| Bonner Michael | Chief Financial Officer | 18454 0.1238% | $1.52 | 9 | 0 | <0.0001% |
| Griggs Jonathan | director | 10803 0.0725% | $1.52 | 0 | 1 | |
| Hamm John M. | Chief Financial Officer | 6800 0.0456% | $1.52 | 1 | 0 | +6.25% |
| Bernard Gordon R | director | 0 0% | $1.52 | 0 | 78 | |
| Lawrence Thomas R | director | 0 0% | $1.52 | 0 | 16 |
Institutional Investor Ownership
| Renaissance Technologies | $912,000.00 | 3.82 | 542,663 | -1.31% | -$12,100.33 | <0.01 | |
| The Vanguard Group | $628,742.00 | 2.64 | 374,251 | 0% | +$0 | <0.0001 | |
| Dimensional Fund Advisors | $600,793.00 | 2.52 | 357,615 | -2.27% | -$13,975.92 | <0.0001 | |
| Bridgeway Capital Management | $481,580.00 | 2.02 | 286,655 | 0% | +$0 | 0.01 | |
| Acadian Asset Management | $315,000.00 | 1.33 | 188,164 | 0% | +$0 | <0.01 | |
| BlackRock | $185,748.00 | 0.78 | 110,564 | -0.38% | -$715.68 | <0.0001 | |
| Geode Capital Management | $142,019.00 | 0.6 | 84,522 | -0.88% | -$1,263.56 | <0.0001 | |
| BNY Mellon | $126,450.00 | 0.53 | 75,268 | 0% | +$0 | <0.0001 | |
| State Street | $56,616.00 | 0.24 | 33,700 | -15.3% | -$10,231.20 | <0.0001 | |
| Two Sigma | $54,482.00 | 0.23 | 32,430 | -1.82% | -$1,007.99 | <0.0001 | |
| Two Sigma Advisers LP | $38,640.00 | 0.16 | 23,000 | -1.71% | -$672.00 | <0.0001 | |
| Northern Trust | $27,448.00 | 0.12 | 16,338 | -10.18% | -$3,109.70 | <0.0001 | |
| Cresset Asset Management Llc | $20,202.00 | 0.09 | 12,025 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $18,940.00 | 0.08 | 11,274 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $9,655.00 | 0.04 | 5,747 | +2.11% | +$199.92 | <0.0001 | |
| Citadel Advisors LLC | $6,085.00 | 0.03 | 3,622 | +2.46% | +$146.16 | <0.0001 | |
| Oakworth Capital Inc | $5,127.00 | 0.02 | 3,052 | 0% | +$0 | <0.0001 | |
| UBS | $3,012.00 | 0.01 | 1,793 | +1,530% | +$2,827.22 | <0.0001 | |
| Advisor Group Holdings Inc | $168.00 | <0.01 | 100 | New | +$168.00 | <0.0001 | |
| JPMorgan Chase | $34.00 | <0.01 | 20 | +66.67% | +$13.60 | <0.0001 | |
| Wells Fargo | $109.00 | <0.01 | 65 | +3.17% | +$3.35 | <0.0001 | |
| Huntington National Bank | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 47 | -65.94% | -$0 | <0.0001 |